Drug Type Small molecule drug |
Synonyms CKD-516, NOV 1204, NOV-120401 |
Target |
Mechanism Tubulin inhibitors, Tubulin polymerisation inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H29ClN6O5S |
InChIKeyFIAUXCMEQTWLQZ-FTBISJDPSA-N |
CAS Registry1240321-53-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory Malignant Solid Neoplasm | Phase 2 | KR | 24 Feb 2021 | |
Advanced Colorectal Adenocarcinoma | Phase 2 | KR | 01 Dec 2016 | |
Colorectal Cancer | Phase 2 | KR | 01 Dec 2016 | |
Advanced Malignant Solid Neoplasm | Phase 1 | KR | 01 Dec 2014 | |
Solid tumor | Phase 1 | KR | 01 Dec 2009 |
Phase 1 | 39 | Irinotecan+CKD-516 | ucfcbktiqq(wqnkjjiuqw) = CKD-516/irinotecan doses of 11/120 mg/m2 xwbtnubarp (tludjfmojm ) View more | Positive | 01 Oct 2021 | ||
Phase 1 | 23 | ezkrbajqtv(royusxqryo) = grade 3 hypertension 2/23 nrjheoivvb (cwjzmfqlkk ) View more | Positive | 01 Jan 2016 |